# Tolerance Through Mixed Chimerism (Sip-Tego)

> **NCT06972069** · EARLY_PHASE1 · RECRUITING · sponsor: **Tatsuo Kawai, MD, PhD** · enrollment: 12 (estimated)

## Conditions studied

- Kidney Failure
- Transplant Recipient (Kidney)
- Transplant Tolerance
- Immunosuppresion
- Immunosuppression After Kidney Transplantation

## Interventions

- **PROCEDURE:** Combined Kidney/Bone Marrow Transplant
- **PROCEDURE:** Donation of Kidney / Bone Marrow
- **DRUG:** Conditioning Regimen (Rituxan, Siplizumab, Cyclophosphamide, Tegoprubart)

## Key facts

- **NCT ID:** NCT06972069
- **Lead sponsor:** Tatsuo Kawai, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-31
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06972069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06972069, "Tolerance Through Mixed Chimerism (Sip-Tego)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06972069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*